Subscribers,

We recently alerted you to Q BioMed, Inc (QBIO) a few months ago back in March, and when we did it exploded north of $2.25 for over 15% gains in just a couple of days.

Now QBIO is back on our radar as it has gradually sold off. We think it could be ready for another bounce higher!

You can see in the six month chart below that QBIO has a history of making some major moves. Back in January it ran from under $1 to almost $2 in just 3 trading sessions - that's a 100% gain in 3 days!!

Then it ran from $1.75 to over $2.50 in about a week - another 40%+ move.

In March it jumped from around $1.60 to around $2.35 for almost 50% gains in a week.

And again in May when it ran from $1.50 to $2.00 for 33% gains in just 3 days.

Talk about a trader's dream come true!!! QBIO is the ticker to watch today, there's no doubt about that.

About Q BioMed...

Q BioMed, Inc. is a biomedical acceleration and development company. They are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need.

QBIO aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. 

Opioid Alternative is FDA-approved and ready to launch the fortunes of Q BioMed

The widespread push to reduce the use of opioids means that clinicians are actively seeking effective alternatives. Opioid addiction is at crisis levels.

But addiction isn’t the only problem with opioids. For those with the most severe pain, there are few alternatives. Yet the side effects of opioids can be so bad that many patients prefer the pain.

Brain fog, nausea, vomiting, abdominal distention, and constipation can be excruciating for opioid users . What’s worse, prolonged use can lead to tolerance, which means the drug is no longer able to mask the pain.

For the hundreds of thousands who suffer with cancer that has spread to bone, Q BioMed’s (OTCQB: QBIO) Metastron offers an alternative to the horrors of opioids.

Metastron is non-addictive, works in 80% of patients, & continues working for 6 months with a single dose

Metastron is specifically designed to target pain caused by cancer that has spread to the bone, which is a common occurrence in the prostate, breast, and lung cancers, among others.

The active ingredient in Metastron is a radioactive isotope of the chemical element strontium. When injected into the body strontium acts like calcium, being taken into the bone at sites of tumors and lesions.

It then delivers radiation directly to the sites, relieving pain.

Q BioMed (OTCQB: QBIO) bought Metastron from GE Healthcare, where it surprisingly never got the marketing push it needed to grow sales, even though Metastron’s development was hailed by the pharmaceutical and biotechnology industries as a “major advance” in pain control.³

Metastron is FDA-approved, as well as approved for sale in 21 other countries. It is reimbursable by Medicare and most health plans.

After FDA approval of Q BioMed’s U.S. based contract manufacturing facility, expected in the second half of 2019, the drug will be rolled out to the market.

The company projects sales to be as high as $150 million within the next five years.⁴ Look for share price to soar as revenues grow. Brookline Capital Markets rates QBIO a Buy with a target price of $16.00.⁵

Next step is to seek approval as a therapeutic drug, giving Q BioMed (OTCQB: QBIO) enormous revenue potential

Importantly, a Phase II clinical trial published in the prestigious medical journal The Lancet showed that cancer patients lived a significant nine monthslonger when given Metastron as a combination therapy. This could be compared to just two months for a competitive blockbuster drug.

A planned Phase IV trial is expected to confirm those results, and will exponentially increase potential revenue for the company and its shareholders.

A similar drug that has a limited application for a relatively small patient population in prostate cancer, and which offers only a small overall survival benefit generates more than $500 million a year in revenue for its manufacturer.

Metastron targets a much larger potential patient universe. The company believes that if clinical trials prove what previous studies have shown, the market for therapeutically prescribed Metastron could be several hundred million dollars. ⁷

Pain associated with bone cancer is an underserved market

Medications for alleviating the pain occurring from cancer comprise more than 25% of the overall pain management therapeutics market, which is set to reach $83 billion by 2024.⁸

The market for bone cancer treatment is even larger than for bone cancer pain control. In 2018 that market reached $62.9 million, and it is projected to grow to $83.8 million by 2024.⁹

While there are several treatments currently available, their effectiveness is often limited for long term pain management, they are associated with several undesirable side effects, and/or are constrained by factors like chemotherapy and health condition of the patient.

Expected sales to grow rapidly

More than 280,000 Americans are living with bone cancer today,¹⁰ with an expected 3,500 new cases diagnosed in 2019.¹¹ If Q BioMed’s (OTCQB: QBIO) Metastron were prescribed to just 2% of all patients, at its estimated $10,000 per dose that would mean $56 million in revenues.

If the drug were approved for bone cancer therapy, the company projects that additional revenues could be as much as $500 million.

What’s more, bone pain can be indicated in other primary cancers as well, and that could be a much bigger market. Q BioMed intends to pursue label expansion to include therapy of other primary cancers as well as in combination with other therapies. This would require additional clinical trials, which could easily be financed with sales revenue.

Metastron is one of two drugs in Q BioMed’s pipeline ready for commercialization, the other being a generic version of Metastron. However, the company has several other promising drugs in development too.

Source: https://markettactic.com/opioid-alternative-is-fda-approved-and-ready-to-launch-the-fortunes-of-q-biomed/2468/

QBIO approaches biopharmaceutical development from a nontraditional angle. Rather than strictly devoting its resources to internal development, the company licenses what it deems to be undervalued biomedical assets in order to accelerate the achievement of clinical and commercial milestones. The company has five assets in its pipeline, led by its cancer palliation program, and diversified across multiple areas of significant medical need, including developmental nonverbal disorder, liver cancer and glaucoma.

Q BioMed Unlocks Undiscovered Biomedical Value

• Targets assets entering validation, clinical stages or commercialization leading up to value creating inflection points
• Deploys performance-based capital and resources to accelerate the development of an asset milestone achievement by its management
• Licenses or acquires the assets and works together to create valuation growth

How Q BioMed Accelerates Biomedical Technology Development

• Unlocks capital in US public markets to fund the development of assets
• Makes liquid investments in high-value assets that can produce exponential returns
• Diversifies risk over several therapies in various stages of development and deploys performance-based capital only
• Accelerates its asset’s development with management and advisory teams' expertise, experience, and industry relationships

You can visit their website at https://qbiomed.com for more information on the Company
 

QBIO has several bullish catalysts working in its favor...

• QBIO's strong corporate leadership led by CEO Denis Coran.

• A growing pipeline and strategy that mitigates risk & drives shareholder value.

• Acquired the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare.The agreement gives QBIO ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorisations will be assigned or transferred to QBIO to allow for as seamless a transition as possible in all markets.

• QBIO anticipates Metastron™ to start generating revenue in 1H 2019, with gross palliation revenue expected to be $20M-$40m p/a in year 3.

• QBIO's QBM-001 treatment for pediatric non-verbal disorder has $5B in global market potential.

• QBIO believes that it will complete formulation and manufacturing of QBM-001 by the end of the second quarter of 2019, after which it will file an investigational new drug (IND) application with the FDA. The company is hopeful that QBM-001 may receive the relevant designations from the FDA that could accelerate the development timeline. Assuming authorization from the FDA for the IND, the company believes it could begin a pivotal clinical trial of QBM-001 in the third quarter of 2019, which could lead to reviewed interim data as early as the first quarter of 2020.

• Technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada. The collaboration is focused on ophthalmic drug delivery and formulation experiments for MAN-01, a first-in-class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery.

Recent Developments...

QBIO has announced some major developments in recent weeks and months, you can read the latest below or head to https://finance.yahoo.com/quote/QBIO to read them all and in full.

Q BioMed Advances QBM-001 for the Treatment of Autism Spectrum Disorder Subtype

NEW YORK, June 04, 2019 (GLOBE NEWSWIRE) -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration company, today announced advancements on several fronts for its key asset, QBM-001, in the treatment of pediatric minimally verbal autism (PMVA), a rare autism spectrum disorder (ASD) for which no effective treatment currently exists. Globally, over 250,000 children are born with PMVA per year, 20,000 of them the U.S. 
 

In a Major Breakthrough, Q BioMed Discovers First Biomarkers for Pediatric Nonverbal Autism Subgroup

NEW YORK, April 10, 2019 (GLOBE NEWSWIRE) -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today the discovery of two novel biomarkers for pediatric nonverbal autism, identified in a subset of children with Autism Spectrum Disorder (ASD). This marks the first time a company has been able to identify biomarkers that hold the potential to stratify this subset of children. The study took into consideration 1,953 potential biomarkers and used Vineland II scores to stratify 240 children into three groups: verbal, semi-verbal, and nonverbal autism.

Q Biomed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression From Washington University

Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) from the Washington University in St. Louis. Determining the severity of glaucoma using this biomarker will aid in treatment decisions for patients diagnosed with, and being treated for, glaucoma. Currently, no single examination or diagnostic test is able to accurately predict disease progression.

Q BioMed's Autism Spectrum Disorder Drug Development Program Featured in February Issue of Leading Pharma/Biotech Newspaper

Q BioMed Inc. (QBIO), a biotechnology acceleration company, today announced that in the February issue of DDNews, journalists conducted an interview with Q BioMed CEO Dennis Corin, focused on the mechanism of action, development path, and market opportunities of QBM-001 which is being developed to help treat rare pediatric non-verbal autism spectrum disorder. DDNews is a respected monthly newspaper dedicated to the news of technology and business in the pharmaceutical and biotechnology industries.

In Conclusion...

We think QBIO has some excellent catalysts for the short and long term future.

The chart appears bullish, and liquidity is excellent.

We urge members to do their research and be ready for the trading day ahead.



All the best.

SmallCapMomo.com

picks@smallcapmomo.com

Remember our key trading rules when trading. Capital preservation is key. Keep your stops tight, and if things don't go your way, cut your losses and look for another opportunity.